Developmental brain disorders studied

Jul 06, 2006

U.S. scientists say a recent genetic study of developmental brain disorders might lead to a better understanding of a number of congenital diseases.

The University of California-Irvine study is the first to find mutations of the structural proteins in brain cells -- beta-actin -- are linked with such disorders as deafness and dystonia. The research also suggests genetic variants of the proteins may play a wider role with inherited human diseases.

The study's lead author, Vincent Procaccio, said the findings provide vital clues to the basis of some developmental disorders and make early diagnosis possible for diseases such as dystonia, allowing for greater treatment opportunities.

"These types of actin proteins are prevalent throughout the body and play a key role in processes that are an essential part of development," said Procaccio, an assistant professor of pediatrics. "To find that these mutations are involved with brain disorders seems to be the tip of an iceberg. Since beta-actin is involved with many developmental cell functions, it would appear that its genetic variants can be involved with a number of other congenital disorders."

Study results appeared in the June issue of the American Journal of Human Genetics.

Copyright 2006 by United Press International

Explore further: Medicare proposes coverage change on short hospital stays

Related Stories

Protein plays unexpected role in embryonic stem cells

Jun 18, 2015

What if you found out that pieces of your front door were occasionally flying off the door frame to carry out chores around the house? That's the kind of surprise scientists at the Salk Institute experienced ...

Research shows blood cells generate neurons in crayfish

Apr 09, 2015

A new study by Barbara Beltz, the Allene Lummis Russell Professor of Neuroscience at Wellesley College, and Irene Söderhäll of Uppsala University, Sweden, published in the August 11 issue of the journal ...

Recommended for you

Diabetes drug helps people lose weight: study

2 hours ago

Liraglutide, an injectable diabetes drug that US regulators approved last year for weight loss, helped obese people lose an average of 18 pounds (eight kilograms), a yearlong study said Wednesday.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.